Q4 2018 Biosyent Inc Earnings Call Transcript
© -
Hello, and welcome to the BioSyent Q4 and Full Year Fiscal '18 Results Presentation. My name is René Goehrum, and I'm the President and CEO of BioSyent.
I want to start today's presentation with a look at our sales EBITDA and net income after tax for the quarter ended December 31. As you can see on the right side of your screen, our sales reached just above $5.9 million. That was essentially flat with year ago but enough to present a new record in quarter of sales. The breakdown for sales for the quarter was a growth of our Canadian pharmaceutical business of 2%, measured in dollars; our International pharmaceutical business was down 2% in dollars; and our legacy business was down 73% for the quarter. The legacy business represents traditionally a small portion of Q4 and certainly, in 2018, it represents an even smaller portion of the year.
Our EBITDA for the quarter was just above $2.1 million. That was up 8% versus year ago. And our net income after tax was $1.67 million, up 15% versus year ago. So this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
